CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings

Background Studies have demonstrated increased risk of major atherothrombotic events in CYP2C19 loss‐of‐function (LOF) variant carriers versus non‐carriers treated with clopidogrel after percutaneous coronary intervention (PCI). We sought to evaluate real‐world outcomes with the clinical implementat...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Amber L. Beitelshees, Cameron D. Thomas, Philip E. Empey, George A. Stouffer, Dominick J. Angiolillo, Francesco Franchi, Sony Tuteja, Nita A. Limdi, James C. Lee, Julio D. Duarte, Rolf P. Kreutz, Todd C. Skaar, James C. Coons, Jay Giri, Caitrin W. McDonough, Rachel Rowland, James M. Stevenson, Thuy Thai, Mark R. Vesely, Jacob T. Wellen, Julie A. Johnson, Almut G. Winterstein, Larisa H. Cavallari, Craig R. Lee
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Wiley 2022-02-01
Reeks:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Onderwerpen:
clopidogrel
CYP2C19
pharmacogenetics
Online toegang:https://www.ahajournals.org/doi/10.1161/JAHA.121.024159
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items